GlobeNewswire

Cloudian Gaining Increased Market Traction in Healthcare and Life Sciences

Share

Will Showcase Storage Solutions to Manage Growing Healthcare Data Volumes Across EMR, EHR and PACS Systems at HIMSS19 Conference

SAN MATEO, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Cloudian, the innovation leader in enterprise object storage, today highlighted its expanding footprint in the healthcare and life sciences market, as organizations around the world turn to the company for help managing their rapidly growing digital assets and realizing the full value of these assets. Over the past year, Cloudian revenue from this market increased 75 percent, and its customer base now includes four national health agencies, one of the largest hospital operators in the U.S., a global pharmaceutical company and a range of other medical facilities and research institutes.

The Cure for Data Storage Ills
The proliferation of healthcare data is enabling advances such as improved diagnoses, new drug discoveries and genetic disease treatments. However, this data typically comes from various sources spread across different systems—from patient medical records in EMR and EHR systems to large amounts of unstructured content such as PET scans, MRIs, CT scans and X-rays in PACS systems—hindering the ability to bring all this data together for analysis and maximize its collective value.

Cloudian’s HyperStore solution provides a limitlessly scalable object storage platform that can consolidate information from these various systems in a cost-effective manner that also complies with HIPPA standards regarding the storage of personal medical information. HyperStore’s benefits include:

  • Public cloud-like flexibility on-premises: Users can start small and non-disruptively add storage nodes as they need more capacity, with the added capacity becoming part of the available storage pool.
  • Data management across the ecosystem: Cloudian seamlessly integrates with healthcare applications and Vendor Neutral Archive solutions to provide a central storage repository, enabling customers to consolidate storage and management of dispersed records and images for real-time, comprehensive viewing.
  • Security and compliance: From data encryption at rest and in transit, to role-based access controls, to WORM (Write Once Read Many) capability, HyperStore includes extensive security features that meet stringent compliance requirements.
  • Metadata tagging: In contrast to traditional SAN and NAS storage, Cloudian’s solution includes rich metadata tagging that greatly facilitates the application of machine learning and analytics for pattern detection, drug and disease research and even diagnoses.
  • Data protection: HyperStore provides up to 14 nines of durability for long-term protection of healthcare and research data.
  • Up to 70 percent cost savings: Built on industry-standard high-density servers, Cloudian reduces storage costs by up to 70 percent compared to traditional enterprise storage and public cloud offerings. 

“Unifying healthcare data within a single repository and making it easily accessible to the right people at the right time is critical to driving more informed decision-making and, ultimately, better patient care,” said Sandra Lillie, global director, enterprise imaging sales and strategy at Hyland. “That’s why we value partners like Cloudian who join forces to break down information silos for our customers, facilitating better collaboration and making the vast stores of medical images, photos and documents available when and where they’re needed.”

HIMSS19 Conference
Cloudian is featuring its HyperStore solution at the HIMSS19 Conference in Orlando, Fla., Feb. 9-15, booth #2888.

About Cloudian
Cloudian turns information into insight with a hyperscale data fabric that lets customers store, find and protect data across the organization and around the globe. Cloudian data management solutions bring cloud technology and economics to the data center with uncompromising data durability, intuitive management tools and the industry’s most compatible S3 API. Cloudian and its ecosystem partners help Global 1000 customers simplify unstructured data management today while preparing for the data demands of AI and machine learning tomorrow. Learn more at www.cloudian.com.

Media Contacts

Jordan Tewell
10Fold Communications
cloudian@10fold.com
415-666-6066

Emily Gallagher
Touchdown PR
cloudian@touchdownpr.com
+44 (0)1252 717040

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CESTPressemelding

Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til ir@hydro.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans

Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CESTPress release

Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to ir@hydro.com. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPressemelding

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPress release

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have

RAPALA VMC CORPORATION’S HALF YEAR REPORT H1/2019: SALES AND PROFITABILITY DECREASED FROM LAST YEAR – FULL YEAR GUIDANCE UNCHANGED19.7.2019 12:00:00 CESTPress release

Rapala VMC Corporation Half year financial report July 19, 2019 at 1:00 p.m. RAPALA VMC CORPORATION’S HALF YEAR REPORT H1/2019: SALES AND PROFITABILITY DECREASED FROM LAST YEAR – FULL YEAR GUIDANCE UNCHANGED January-June (H1) in brief: Net sales were 141.2 MEUR, down 1% from previous year (142.5). With comparable exchange rates sales were 2% lower than last year. Operating profit was 11.4 MEUR (15.3), down 25%.1) Comparable operating profit* was 12.0 MEUR (15.2), down 21%. 1) Cash flow from operations was 11.5 MEUR (5.9). 2) Earnings per share was 0.17 EUR (0.23), down 26%. Full year guidance unchanged: Full year net sales with comparable FX rates expected to be around last year’s level and comparable operating profit* to increase from last year. Strong second half of the year expected: record strong order book in North America, improvements in Indonesian lure factory combined with rigorous management of fixed costs. Uncertainties and risks relate to US-China trade relations, global ec

Scientific Beta defends the role of the Size factor in multi-factor portfolios19.7.2019 11:32:00 CESTPress release

Scientific Beta defends the role of the Size factor in multi-factor portfolios Research shows that omitting the Size factor would be costly for investors New research from Scientific Beta, the smart beta index provider, has shown that the Size factor improves model fit, delivers a significant positive premium in the presence of other factors, and contributes positively to the performance of multi-factor portfolios. The Size effect is well established in the finance literature: stocks with smaller market capitalisation outperform large stocks over the long term. However, a common recommendation in the asset management industry is to remove Size from the factor menu, given its relatively weak post-publication performance. Scientific Beta's analysis differs from recent studies by smart beta providers in assessing the relevance of the Size factor. Rather than asking which factor has the best stand-alone performance, we ask what the marginal impact of the Size factor is when including it in